Last reviewed · How we verify
R-Evolution Worldwide S.r.l. Impresa Sociale — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| albendazole and praziquantel | albendazole and praziquantel | marketed | Anthelmintic combination | β-tubulin (albendazole); calcium channels (praziquantel) | Infectious Disease / Parasitology |
Therapeutic area mix
- Infectious Disease / Parasitology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for R-Evolution Worldwide S.r.l. Impresa Sociale:
- R-Evolution Worldwide S.r.l. Impresa Sociale pipeline updates — RSS
- R-Evolution Worldwide S.r.l. Impresa Sociale pipeline updates — Atom
- R-Evolution Worldwide S.r.l. Impresa Sociale pipeline updates — JSON
Cite this brief
Drug Landscape (2026). R-Evolution Worldwide S.r.l. Impresa Sociale — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/r-evolution-worldwide-s-r-l-impresa-sociale. Accessed 2026-05-17.